Receptors, Tumor Necrosis Factor
"Receptors, Tumor Necrosis Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface receptors that bind TUMOR NECROSIS FACTORS and trigger changes which influence the behavior of cells.
| Descriptor ID |
D018124
|
| MeSH Number(s) |
D12.776.543.750.705.852.760
|
| Concept/Terms |
Receptors, Tumor Necrosis Factor- Receptors, Tumor Necrosis Factor
- Receptors, Cachectin
- Tumor Necrosis Factor Receptors
- TNF Receptor
- Receptor, TNF
- TNF Receptors
- Tumor Necrosis Factor Receptor
- Cachectin Receptors
- Receptors, TNF
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Tumor Necrosis Factor".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Tumor Necrosis Factor".
- Receptors, Tumor Necrosis Factor
- B-Cell Activation Factor Receptor
- B-Cell Maturation Antigen
- CD40 Antigens
- Etanercept
- fas Receptor
- Glucocorticoid-Induced TNFR-Related Protein
- Ki-1 Antigen
- Lymphotoxin beta Receptor
- Receptor Activator of Nuclear Factor-kappa B
- Receptors, Ectodysplasin
- Receptors, OX40
- Receptors, TNF-Related Apoptosis-Inducing Ligand
- Receptors, Tumor Necrosis Factor, Member 14
- Receptors, Tumor Necrosis Factor, Member 25
- Receptors, Tumor Necrosis Factor, Type I
- Receptors, Tumor Necrosis Factor, Type II
- Transmembrane Activator and CAML Interactor Protein
- Tumor Necrosis Factor Decoy Receptors
- Tumor Necrosis Factor Receptor Superfamily, Member 7
- Tumor Necrosis Factor Receptor Superfamily, Member 9
- TWEAK Receptor
This graph shows the total number of publications written about "Receptors, Tumor Necrosis Factor" by people in this website by year, and whether "Receptors, Tumor Necrosis Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 3 | 1 | 4 |
| 2000 | 2 | 2 | 4 |
| 2001 | 4 | 3 | 7 |
| 2002 | 1 | 6 | 7 |
| 2003 | 1 | 4 | 5 |
| 2004 | 2 | 1 | 3 |
| 2005 | 1 | 2 | 3 |
| 2006 | 3 | 1 | 4 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 3 | 4 |
| 2009 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 3 | 3 |
| 2013 | 1 | 2 | 3 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 1 | 2 |
| 2018 | 0 | 1 | 1 |
| 2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Tumor Necrosis Factor" by people in Profiles.
-
Metabolic targeting of NRF2 potentiates the efficacy of the TRAP1 inhibitor G-TPP through reduction of ROS detoxification in colorectal cancer. Cancer Lett. 2022 11 28; 549:215915.
-
Acute and Chronic Effects of Adjuvant Therapy on Inflammatory Markers in Breast Cancer Patients. JNCI Cancer Spectr. 2022 07 01; 6(4).
-
A four-gene transcript score to predict metastatic-lethal progression in men treated for localized prostate cancer: Development and validation studies. Prostate. 2019 10; 79(14):1589-1596.
-
Genetic Polymorphism in Cytokines and Costimulatory Molecules in Stem Cell and Solid Organ Transplantation. Clin Lab Med. 2019 03; 39(1):107-123.
-
TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015 Apr 18; (4):CD005468.
-
Muscle inflammation susceptibility: a prognostic index of recovery potential after hip arthroplasty? Am J Physiol Endocrinol Metab. 2015 Apr 15; 308(8):E670-9.
-
OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. J Am Acad Dermatol. 2015 Jan; 72(1):115-22.
-
Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1426-34.
-
Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. J Rheumatol. 2014 Jun; 41(6):1163-70.
-
The tumour suppressor Ras-association domain family protein 1A (RASSF1A) regulates TNF-a signalling in cardiomyocytes. Cardiovasc Res. 2014 Jul 01; 103(1):47-59.